Bupropion for the treatment of nicotine withdrawal and craving (Q36532139)

14 August 2017

1 reference

title

Bupropion for the treatment of nicotine withdrawal and craving (English)

1 reference

14 August 2017

0 references

1 reference

Marc E Mooney

1

1 reference

14 August 2017

Mehmet Sofuoglu

series ordinal

2

1 reference

14 August 2017

publication date

1 July 2006

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

14 August 2017

published in

1 reference

14 August 2017

volume

6

1 reference

14 August 2017

issue

7

1 reference

14 August 2017

page(s)

965-981

1 reference

Role of smoking in global and regional cancer epidemiology: current patterns and data needs

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.965

Role of smoking in global and regional cardiovascular mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.965

Have we lost our way? The need for dynamic formulations of smoking relapse proneness

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.965

Relapse and maintenance issues for smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.965

Nicotine dependence: studies with a laboratory model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.965

Neurobiology of the nicotine withdrawal syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.965

Dramatic decreases in brain reward function during nicotine withdrawal

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.965

Mecamylamine-precipitated nicotine-withdrawal aversion in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.965

21 January 2018

Craving for cigarettes

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.965

Tobacco withdrawal symptoms: an experimental analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.965

Nicotine withdrawal versus other drug withdrawal syndromes: similarities and dissimilarities

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.965

The development and initial validation of a questionnaire on smoking urges

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.965

Predicting relapse back to smoking: contrasting affective and physical models of dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.965

Postcessation cigarette use: the process of relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.965

Opponent process theory of motivation: neurobiological evidence from studies of opiate dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.965

Reactivity to smoking cues: mediating roles of nicotine dependence and duration of deprivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.965

Neural mechanisms underlying nicotine addiction: acute positive reinforcement and withdrawal

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.965

Current pharmacological treatments for nicotine dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.965

The neurobiological basis for partial agonist treatment of nicotine dependence: varenicline.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.965

How does bupropion work as a smoking cessation aid?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.965

A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.965

A placebo controlled trial of bupropion for smoking cessation in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.965

A preliminary study of bupropion sustained-release for smoking cessation in patients with chronic posttraumatic stress disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.965

Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.965

Bupropion SR for smoking cessation in smokers with cardiovascular disease: a multicentre, randomised study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.965

Acute doses of d-amphetamine and bupropion increase cigarette smoking

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.965

Effectiveness of bupropion sustained release for smoking cessation in a health care setting: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.965

Behavioral and biochemical investigations of bupropion metabolites

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.965

Effect of nicotine and nicotinic receptors on anxiety and depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.965

The role of reward pathways in the development of drug dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.965

In vivo activity of bupropion at the human dopamine transporter as measured by positron emission tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.965

Bupropion occupancy of the dopamine transporter is low during clinical treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.965

Bupropion enhances brain reward function and reverses the affective and somatic aspects of nicotine withdrawal in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.965

Attenuation of cue-induced cigarette craving and anterior cingulate cortex activation in bupropion-treated smokers: a preliminary study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.965

Brain substrates for increased drug seeking during protracted withdrawal

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.965

Adolescent nicotine exposure produces immediate and long-term changes in CNS noradrenergic and dopaminergic function

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.965

Cigarette craving, smoking withdrawal, and clonidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.965

Modification of norepinephrine and serotonin, but not dopamine, neuron firing by sustained bupropion treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.965

Enantioselective effects of hydroxy metabolites of bupropion on behavior and on function of monoamine transporters and nicotinic receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.965

Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.965

Mecamylamine combined with nicotine skin patch facilitates smoking cessation beyond nicotine patch treatment alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.965

Steady-state pharmacokinetics of bupropion SR in juvenile patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.965

Nicotine and bupropion share a similar discriminative stimulus effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.965

Characterization of the effects of bupropion on the reinforcing properties of nicotine and food in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.965

Effect of bupropion on nicotine self-administration in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.965

Investigating the actions of bupropion on dependence-related effects of nicotine in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.965

Nicotine, negative affect, and depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.965

Effects of nicotine on the threshold for rewarding brain stimulation in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.965

Addiction motivation reformulated: an affective processing model of negative reinforcement

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.965

Recommendation for the assessment of tobacco craving and withdrawal in smoking cessation trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.965

Nicotine and nonnicotine factors in cigarette addiction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.965

Incubation of cocaine craving after withdrawal: a review of preclinical data

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.965

Naltrexone reduces the relative reinforcing value of nicotine in a cigarette smoking choice paradigm

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.965

The effect of bupropion on nicotine craving and withdrawal

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.965

Effect of sustained-release (SR) bupropion on craving and withdrawal in smokers deprived of cigarettes for 72 h.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.965

Time course of cigarette withdrawal symptoms while using nicotine gum.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.965

Naltrexone blockade of nicotine effects in cigarette smokers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.965

Naltrexone alteration of acute smoking response in nicotine-dependent subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.965

Evaluation of the brief questionnaire of smoking urges (QSU-brief) in laboratory and clinical settings

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.965

Variation in bupropion findings is not due to differences in measurement: comment on Teneggi et al.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.965

Medication screening for smoking cessation: a proposal for new methodologies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.965

Environments as cues to smoke: implications for human extinction-based research and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.965

The moderator–mediator variable distinction in social psychological research: Conceptual, strategic, and statistical considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.965

Effect of bupropion on depression symptoms in a smoking cessation clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.965

Mediating mechanisms for the impact of bupropion in smoking cessation treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.965

Nicotine patch therapy based on smoking rate followed by bupropion for prevention of relapse to smoking

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.965

Randomized clinical trial of the efficacy of bupropion combined with nicotine patch in the treatment of adolescent smokers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.965

Bupropion for smoking cessation: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.965

Effects of sustained-release bupropion among persons interested in reducing but not quitting smoking

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.965

Bupropion SR as an aid to smoking cessation in smokers treated previously with bupropion: a randomized placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.965

Psychological intervention and antidepressant treatment in smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.965

Efficacy of bupropion and nortriptyline for smoking cessation among people at risk for or with chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.965

Effects of sustained-release bupropion and supportive group therapy on cigarette consumption in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.965

Sustained-release bupropion for smoking cessation in African Americans: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.965

A multicentre, randomized, double-blind, placebo-controlled, 1-year study of bupropion SR for smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.965

Addressing women's concerns about weight gain due to smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.965

Smoking, body weight, and their effects on smoking behavior: a comprehensive review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.965

A pilot trial of bupropion added to cognitive behavioral therapy for smoking cessation in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.965

The effect of bupropion sustained-release on cigarette craving after smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.965

Development of major depression after treatment for smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.965

A double-blind placebo-controlled cross over trial of bupropion in smoking reduction in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.965

Effects of dopamine transporter and receptor polymorphisms on smoking cessation in a bupropion clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.965

Pharmacogenetic investigation of smoking cessation treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.965

Pharmacokinetic optimisation of sustained-release bupropion for smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.965

Estimates of global mortality attributable to smoking in 2000

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.965

Tolerability and safety of sustained-release bupropion in the management of smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.965

Noradrenaline in the ventral forebrain is critical for opiate withdrawal-induced aversion

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.965

21 January 2018

Identifiers

DOI

10.1586/14737175.6.7.965

1 reference

14 August 2017

1 reference